Partnering
Partner on a new target class
Most ADC companies compete on payloads and linkers. Tacalyx works one step earlier, on the target: tumor glycans that few teams can raise good antibodies against.
01What we offer
Ways to work together
- Target and antibody access TACA targets and high-affinity antibodies for your own modality and payload.
- Co-development Joint development of ADCs, T-cell engagers and multi-specifics against TACAs.
- Research collaborations Glycan synthesis, antibody discovery and target validation with academic and industry partners, such as the LUMC collaboration on colorectal cancer glycans.
02What partners get
Why a TACA programme
- First-in-class targets
- A largely untapped target class for ADC and T-cell engager pipelines, independent of payload and linker choices.
- Two modalities in-house
- TCX-201 shows the approach as an ADC, TCX-101 as a trispecific T-cell engager, both with preclinical data presented at AACR.
- Proprietary platform
- Synthetic glycan structures and antibodies from a platform based on licenses from Max-Planck-Innovation.
- ADC development experience
- CEO Jean Engela previously ran NBE Therapeutics and led oncology development programmes at Boehringer Ingelheim.
03Programmes
What is in development
Next milestone Next clinical candidate selection End 2026
First clinical candidate
TCX-201
- Modality
- ADC
- Target
- Undisclosed protein-linked TACA
- Indication
- Gastrointestinal malignancies and other solid tumors
- Stage
- IND/CTA-enabling
The target glycan sits on proteins, is highly expressed in pancreatic, gastric and colorectal cancer and internalizes quickly, which suits payload delivery. In preclinical models the ADC reduced tumor growth dose-dependently in cell line- and patient-derived xenografts, including a metastatic colorectal cancer PDX, showed an antibody-like half-life of about five days and was well tolerated in a single-dose study in non-human primates. Selected in April 2026 as Tacalyx's first clinical candidate.
Latest data
Next milestone
CTA filing Planned 2027
T-cell engager programme
TCX-101
- Modality
- Trispecific TCE
- Target
- Undisclosed sphingolipid-linked TACA and a tumor-associated protein antigen
- Indication
- Solid tumors
- Stage
- Preclinical
The TACA behind TCX-101 is anchored to sphingolipids and highly expressed in colon, lung, ovarian and breast cancer. It internalizes slowly, and an ADC format showed limited efficacy, so Tacalyx moved the antibody into T-cell engager formats: a 2+1 CD3 CrossMab in 2025, now a trispecific that binds the TACA and a tumor-associated protein antigen. In knockout cell lines, binding and T-cell-mediated killing depend on both targets.
Latest data
Next milestone
To be announced
Discovery programme
Target F
- Modality
- Modality open
- Target
- Undisclosed TACA
- Indication
- Solid tumors
- Stage
- Preclinical
An antibody against a further TACA, in early preclinical work. The modality follows the target's biology, as with TCX-201 and TCX-101.
Next milestone
To be announced
Discovery programme
Target C
- Modality
- Modality open
- Target
- Undisclosed TACA
- Indication
- Solid tumors
- Stage
- Lead optimization
Target discovery completed; antibodies against this TACA are entering lead optimization.
Next milestone
To be announced
Discovery programme
Target E
- Modality
- Modality open
- Target
- Undisclosed TACA
- Indication
- Solid tumors
- Stage
- Lead optimization
Target discovery completed; antibodies against this TACA are entering lead optimization.
Next milestone
To be announced
Discovery programme
Target D
- Modality
- Modality open
- Target
- Undisclosed TACA
- Indication
- Solid tumors
- Stage
- Target discovery
Target discovery and antibody generation against a further TACA.
Next milestone
To be announced
04Where to meet us
Meet us at upcoming conferences
Planning a partnering meeting? Tell us in the form below and we will set up a time.
- BIO-Europe November 2026
- J.P. Morgan Healthcare Conference January 2027 · San Francisco
- AACR Annual Meeting April 2027
05Contact